Business Context and Reporting Period
Company: AirSculpt Technologies, Inc. (AIRS)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2024
Business Overview: AirSculpt operates a network of 32 centers across 20 U.S. states, Canada, and the United Kingdom, providing minimally invasive body contouring procedures. The company utilizes a proprietary, patented method that requires no needles, scalpels, or general anesthesia. Revenue is generated exclusively through 100% private pay, with no reimbursement risk from government or private insurers.
Key Financial Metrics
| Metric | 2024 | 2023 | Change |
|---|---|---|---|
| Revenue | $180.4 million | $195.9 million | (7.9)% |
| Net Loss | $(8.3) million | $(4.5) million | Widened |
| Adjusted EBITDA | $20.7 million | $43.2 million | (52.1)% |
| Adjusted EBITDA Margin | 11.5% | 22.1% | (10.6) pts |
| Operating Cash Flow | $11.4 million | $24.0 million | (52.5)% |
| Cash and Equivalents | $8.2 million | $10.3 million | (20.4)% |
| Total Debt (Principal) | $75.8 million | $72.9 million | Increased |
| Working Capital | $(11.5) million | $(4.4) million | Negative |
Operational Metrics:
- Cases Performed: 14,036 (2024) vs. 14,932 (2023), a decline of 6.0%.
- Revenue per Case: $12,849 (2024) vs. $13,121 (2023), a decline of 2.1%.
- Same-Center Volume: Declined 13.7% in 2024.
- Customer Acquisition Cost: $3,130 per customer in 2024.
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased by $15.6 million (7.9%) primarily due to weaker performance across the broader aesthetics and high-end retail industries, resulting in a 13.7% drop in same-center case volume.
- Profitability Compression: Adjusted EBITDA margin contracted significantly from 22.1% to 11.5% due to the revenue decline and an inability to leverage fixed costs, alongside increased marketing investments.
- Leadership Transition: Todd Magazine stepped down as CEO in August 2024. Yogi Jashnani was appointed CEO in January 2025 to drive revenue growth strategies.
- Cost Reduction: The company implemented a cost reduction program estimated to eliminate approximately $3 million in annual overhead and contracted expenses.
- Debt Structure: The company drew $5.0 million on its revolving credit facility in 2024, leaving no availability as of year-end. Total debt increased slightly due to revolver usage.
Guidance, Outlook, Risks, and Unusual Items
Management Commentary and Strategy
Management is focusing on stabilizing revenue growth through optimized marketing investments (shifting to returns-based approaches), improving go-to-market strategies, expanding consumer financing options, and introducing new product innovations, particularly in skin tightening. The company does not plan to open new centers in the near term to improve liquidity.
Debt Covenants and Liquidity (Subsequent Event)
On March 12, 2025, the company entered into a Third Amendment to its Credit Agreement. Key terms include:
- Covenant Modifications: The Consolidated Fixed Charge Coverage Ratio requirement was lowered to 0.50x for Q1 2025 and 1.10x for Q2 2025 (previously 1.10x and 1.25x). The Consolidated Leverage Ratio cap was increased to 4.25x for Q1 2025.
- Liquidity Requirements: The company must maintain minimum liquidity of $3.0 million by March 31, 2025, rising to $7.5 million by May 31, 2025.
- Interest Rate Impact: Beginning July 1, 2025, interest rate margins will increase based on leverage ratios, potentially reaching 4.75% over SOFR if leverage exceeds 3.00x.
- Sponsor Guarantee: The private equity sponsor (Vesey Street Capital Partners) provided a $10.0 million limited guarantee of the company's obligations, callable if the company fails to prepay $10.0 million of the term loan by June 15, 2025.
Risk Factors
- Competition from Weight-Loss Drugs: Increased market acceptance of GLP-1 weight-loss drugs may impact demand for body contouring, though management believes it could also drive demand for skin tightening procedures.
- Regulatory Risks: Changes in laws regarding the corporate practice of medicine or fee-splitting could require restructuring of relationships with Professional Associations.
- Supply Chain: Reliance on a single third-party manufacturer (Euromi) for the proprietary handpiece used in procedures.
- California Exposure: Five centers in California represented 20% of 2024 revenue; recent wildfires in Southern California pose a risk to operations in that region.
Investor Verification Checklist
- Liquidity Position: Verify the company's ability to meet the new minimum liquidity covenants ($3M-$7.5M) required under the March 2025 debt amendment.
- Revenue Stabilization: Monitor same-center volume trends in Q1 and Q2 2025 to assess the effectiveness of the new CEO's marketing and sales strategies.
- Debt Service Costs: Evaluate the impact of the increased interest rate margins effective July 2025 on future cash flows, given the current leverage ratio.
- California Operations: Assess the financial impact of the Southern California wildfires on the five centers comprising 20% of revenue.
- Cost Savings Realization: Confirm the actual realization of the estimated $3 million in annual cost reductions.